Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q1 FY27 Earnings Presentation
17 slides from Gland Pharma's earnings presentation, Aug 10, 2026
Slide 1: Investor Presentation Q1 FY27
GLAND PHARMA Investor Presentation Q1 FY27 10th August 2026
Slide 2: Safe Harbour Statement
Safe Harbour Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendatio
Slide 3: Financial Highlights
in Financial Highlights
Slide 4: Consolidated P&L
Consolidated P&L ₹ Mn Particulars Q1 FY27 Q1 FY26 YoY Q4 FY26 QoQ Revenue from operations 18,003 15,056 20% 17,428 3% Other Income 612 575 6% 1,115 -45% Total Income 18,615 15,631 19% 18,543 0% Gross Profit(1) 11,759 9,845 19% 11,515 2% Gross Profit margin (%) 65% 65% 66% EBITDA(2) 4,930 3,678 34% 5
Slide 5: Consolidated Financial Highlights (1/3)
Consolidated Financial Highlights (1/3) Revenue from Operations Gross Profit(1) / Gross Profit Margin(2) (₹ Mn) (₹ Mn / %) 17,428 18,003 11,515 11,759 15,056 9,845 66% 65% 65% Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Adj. EBITDA(3) / Adj. EBITDA Margin(4) / PAT / PAT Margin R&D Expenditure (₹
Slide 6: Consolidated Financial Highlights (2/3)
Consolidated Financial Highlights (2/3) Net Worth(1) ROCE(2) / RONW(3) (₹ Mn) (%) RoCE RoNW 91,507 103,580 106,762 14% 15.0% 9% 11% 12% 10.0% 11% 8% 5.0% 0.0% FY25 FY26 Jun'26 FY25 FY26 Jun'26 Capital Expenditure Asset Turnover Ratio(4)(5) (₹ Mn) (x) 1,373 1,132 1.5 1.6 1.4 786 0.5 0.5 0.6 Total ass
Slide 7: Consolidated Financial Highlights (3/3)
Consolidated Financial Highlights (3/3) Cash and Bank Balances / Net Cash(1) Cash Flow from Operations (₹ Mn) Total Cash (₹ Mn) Net Cash 4,045 33,591 35,466 32,939 31,157 3,183 25,562 2,620 22,870 FY25* FY26 Jun'26 Q1 FY26 Q4 FY26 Q1 FY27 . * Excluding non-callable deposits of INR 3,960 million. Net
Slide 8: Business Update
in Business Update
Slide 9: Business-wise Revenue Break-up
Business-wise Revenue Break-up ₹ Mn Business Q1 FY27 Q1 FY26 YoY Q4 FY26 QoQ CDMO 8,915 7,411 20% 8,059 11% B2B* 9,088 7,645 19% 9,369 -3% Total 18,003 15,056 20% 17,428 3% Revenue Distribution Business Update • CDMO growth supported by recent product launches. Q1 Q1 Q4 46% 50% 50% 51% 49% 54% FY27
Slide 10: Business Updates
Business Updates • R&D Expenses: Total R&D expenses were ₹772 million in Q1 FY27, representing 4% of consolidated revenue. The R&D expenditure was mainly focused on complex product development and the number of filings. • New Launches: The company launched 4 molecules in the USA this quarter, includ
Slide 11: Geographical Revenue
SS Geographical — Revenue |
Slide 12: US Market
US Market ₹ Mn Revenue Contribution CDMO B2B 32% YoY 48% YoY 27% YoY 2,653 7,571 7,157 9,807 9,810 2,236 5,649 1,794 7,443 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 US Filings Update US Contribution Business Update Q1FY27 Cumulative • CDMO: Growth driven by recent produ
Slide 13: Europe Market
Europe Market ₹ Mn Revenue Contribution CDMO B2B 20% YoY 20% YoY 6% YoY 36 38 3,814 3,954 3,791 3,916 3,302 3,267 23 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Europe Contribution Business Update • Volume expansion in existing products, including 22% Daptomycin and Cenex
Slide 14: Other Core Markets (Canada, Australia and New Zealand)
Other Core Markets (Canada, Australia and New Zealand) ₹ Mn Revenue Contribution CDMO B2B -28% YoY -45% YoY -11% YoY 739 363 376 314 335 588 534 274 199 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Other Core Markets Contribution Business Update 3% • Volume decline in the
Slide 15: Rest of the World
Rest of the World ₹ Mn Revenue Contribution CDMO B2B 2% YoY -1% YoY 6% YoY 1,677 1,301 1,375 2,978 3,039 1,664 1,209 2,549 1,340 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 RoW Contribution Business Update • Growth seen across some of the key 17% products, including Hepar
Slide 16: India
India ₹ Mn Revenue Contribution CDMO B2B* 12% YoY 56% YoY -36% YoY 284 670 666 483 251 594 419 183 310 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 India Contribution Business Update • Growth seen in CDMO for certain products, 4% including Huminsulin. Q1 • Decline in B2B d
Slide 17: Thank You
GLAND PHARMA Thank You Investor Relations Corporate Office Sampath Kumar Pallerlamudi Gland Pharma Limited Company Secretary & Compliance Officer Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Shriniwas P. Dange Sangareddy District Investor Relations Hyderabad 502307, Telangana,